Depomed Announces Submission Of New Drug Application For Investigational Postherpetic Neuralgia Treatment DM-1796
Depomed, Inc. (NASDAQ: DEPO) announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side ...
Read more on Medical News Today
Stability eludes mom, jeopardizing baby’s return
A young mother of three makes the painful decision to send her newborn daughter to live with a family she’s just met while she begins a quest to find work and a place to live. It’s supposed to be a temporary arrangement. But what will happen when things begin to fall apart?
Read more on The Decatur Daily
Posted in 
